Comparison of cost-effectiveness of implantable cardioverter defibrillator therapy in patients for primary prevention in Latin America: an analysis using the Improve SCA study

References

• Al-Khatib SM, Hellkamp A, Bardy GH, et al. Survival of patients receiving a primary prevention implantable cardioverter-defibrillator in clinical practice vs clinical trials. JAMA. 2013;309(1):55–62.
   PubMed Web of Science ®Google Scholar
• Epstein AE, DiMarco JP, Ellenbogen KA, et al. ACC/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (writing committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and Society of Thoracic Surgeons. Circulation. 2008;117(21):e350-408–2840.
   PubMed Web of Science ®Google Scholar
• Priori SG, Blomstrom-Lundqvist C, Mazzanti A, et al. 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: the task force for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death of the European Society of Cardiology (ESC). Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC). Eur Heart J. 2015;36(41):2793–2867.
   PubMed Web of Science ®Google Scholar
• Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med. 2005;352(3):225–237.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Schuger C, Beck CA, et al. Reduction in inappropriate therapy and mortality through ICD programming. N Engl J Med. 2012;367(24):2275–2283.
   PubMed Web of Science ®Google Scholar
• Cowie MR, Marshall D, Drummond M, et al. Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace. 2009;11(6):716–726.
   PubMed Web of Science ®Google Scholar
• Mark DB, Nelson CL, Anstrom KJ, et al. Cost-effectiveness of defibrillator therapy or amiodarone in chronic stable heart failure: results from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation. 2006;114(2):135–142.
   PubMed Web of Science ®Google Scholar
• Zhang S, Ching C-K, Huang D, et al. Utilization of implantable cardioverter-defibrillators for the prevention of sudden cardiac death in emerging countries: improve SCA clinical trial. Heart Rhythm. 2020;17(3):468–475.
   PubMed Web of Science ®Google Scholar
• Zhang S, Singh B, Rodriguez DA, et al. Improve the prevention of sudden cardiac arrest in emerging countries: the Improve SCA clinical study design. Europace. 2015;17(11):1720–1726.
   PubMed Web of Science ®Google Scholar
• Giedion U, Tristao I, Escobar L, et al. Health benefit plans in Latin America: a regional comparison. Washington DC. Inter-american Development Bank; 2014.
   Google Scholar
• Hammill SC, Kremers MS, Stevenson LW, et al. Review of the registry's fourth year, incorporating lead data and pediatric ICD procedures, and use as a national performance measure. Heart Rhythm. 2010;7(9):1340–1345.
   PubMed Web of Science ®Google Scholar
• Saeed M, Hanna I, Robotis D, et al. Programming implantable cardioverter-defibrillators in patients with primary prevention indication to prolong time to first shock: results from the PROVIDE study. J Cardiovasc Electrophysiol. 2014;25(1):52–59.
   PubMed Web of Science ®Google Scholar
• Gasparini M, Proclemer A, Klersy C, et al. Effect of long-detection interval vs standard-detection interval for implantable cardioverter-defibrillators on antitachycardia pacing and shock delivery: the ADVANCE III randomized clinical trial. JAMA. 2013;309(18):1903–1911.
   PubMed Web of Science ®Google Scholar
• Moss AJ, Zareba W, Hall WJ, et al. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12):877–883.
   PubMed Web of Science ®Google Scholar
• Ghani A, Delnoy PPHM, Ramdat Misier AR, et al. Incidence of lead dislodgement, malfunction and perforation during the first year following device implantation. Neth Heart J. 2014;22(6):286–291.
   PubMed Web of Science ®Google Scholar
• Providencia R, Kramer DB, Pimenta D, et al. Transvenous implantable cardioverter-defibrillator (ICD) lead performance: a meta-analysis of observational studies. J Am Heart Assoc. 2015;4(11):2047–9980.
   Web of Science ®Google Scholar
• Li H, Natale A, Zhu W, et al. Causes and consequences of discontinuation of the implantable cardioverter-defibrillator therapy in non-terminally ill patients. Am J Cardiol. 1998;81(10):1203–1205.
   PubMed Web of Science ®Google Scholar
• EL E, Lgs B, Mp J. Economic impact of cardiac implantable electronic device infections: cost analysis at one year in a large US health insurer. J Med Econ. 2020;23(7):698–705.
   PubMed Web of Science ®Google Scholar
• Hussein AA, Baghdy Y, Wazni OM, et al. Microbiology of cardiac implantable electronic device infections. JACC Clin Electrophysiol. 2016;2(4):498–505.
   PubMedGoogle Scholar
• Tamayo D, Rodríguez V, Rojas M. Outpatient and inpatient costs of heart failure in two hospitals in Bogotá. Acta Med Colomb. 2013;38(4):208–212.
   Google Scholar
• Poole JE, Gleva MJ, Mela T, et al. Complication rates associated with pacemaker or implantable cardioverter-defibrillator generator replacements and upgrade procedures: results from the REPLACE registry. Circulation. 2010;122(16):1553–1561.
   PubMed Web of Science ®Google Scholar
• Evaluación de Tecnologías para la Salud: Documento Metodologico. Centro Nacional de Excelencia Tecnologica en Salud; 2017. Available from: http://www.cenetec.salud.gob.mx/descargas/detes/metodologico_ETES.pdf
   Google Scholar
• Mabel MV, Aurelio MM, Hectro ECJ. Manual para la elaboracion de evaluaciones economicas en salud. Bogotá DC: Instituo de Evaluacion Tecnologica en Salud; 2014.
   Google Scholar
• Guía metodológica para estudios de evaluación económica de tecnologías sanitarias. MERCOSUR; 2013. (Resolución N° 03/13). Available from: http://www.sice.oas.org/trade/mrcsrs/resolutions/Res0313_s.pdf
   Google Scholar
• Auricchio A, Schloss EJ, Kurita T, et al. Low inappropriate shock rates in patients with single- and dual/triple-chamber implantable cardioverter-defibrillators using a novel suite of detection algorithms: PainFree SST trial primary results. Heart Rhythm. 2015;12(5):926–936.
   PubMed Web of Science ®Google Scholar
• Zarate V, Kind P, Chuang L-H. Hispanic valuation of the EQ-5D health states: a social value set for Latin Americans. Value Health. 2008;11(7):1170–1177.
   PubMed Web of Science ®Google Scholar
• Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471–1480.
   PubMed Web of Science ®Google Scholar
• Hutubessy R, Chisholm D, Edejer TT-T. Generalized cost-effectiveness analysis for national-level priority-setting in the health sector. Cost Eff Resour Alloc. 2003;1(1):8.
   PubMedGoogle Scholar
• Wherry K, Holbrook R, Higuera L, et al. Cost-Effectiveness analysis of implantable cardioverter defibrillator therapy for primary prevention patients with additional risk factors in Brazil. Int J Cardiovasc Sci. Forthcoming.
   Google Scholar
• Thijssen J, van den Akker van Marle ME, Borleffs CJW, et al. Cost-effectiveness of primary prevention implantable cardioverter defibrillator treatment: data from a large clinical registry. Pacing Clin Electrophysiol. 2014;37(1):25–34.
   PubMed Web of Science ®Google Scholar
• Mond HG, Proclemer A. The 11th world survey of cardiac pacing and implantable cardioverter-defibrillators: calendar year 2009-a World Society of Arrhythmia's project. Pacing Clin Electrophysiol. 2011;34(8):1013–1027.
   PubMed Web of Science ®Google Scholar
• Raatikainen MJP, Arnar DO, Zeppenfeld K, et al. Statistics on the use of cardiac electronic devices and electrophysiological procedures in the European Society of Cardiology countries: 2014 report from the European Heart Rhythm Association. Europace. 2015;17 Suppl 1 (Suppl 1(16):i1–75.
   PubMed Web of Science ®Google Scholar
• Sweeney MO, Wathen MS, Volosin K, et al. Appropriate and inappropriate ventricular therapies, quality of life, and mortality among primary and secondary prevention implantable cardioverter defibrillator patients: results from the Pacing Fast VT REduces Shock ThErapies (PainFREE Rx II) trial. Circulation. 2005;111(22):2898–2905.
   PubMed Web of Science ®Google Scholar
• Turakhia MP, Zweibel S, Swain AL, et al. Healthcare utilization and expenditures associated with appropriate and inappropriate implantable defibrillator shocks. Circ Cardiovasc Qual Outcomes. 2017;10(2):1941–7713.
   Web of Science ®Google Scholar